KELYB vs ORN

KELYB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, placing it firmly in the 'Weak' health category. While the stock appears undervalued on a Price-to-Book (0.55) and Price-to-Sales (0.13) basis, this is likely a value trap given the negative profit margins (-5.98%) and contracting revenue (-11.90%). The combination of a negative ROE (-22.98%) and significant insider selling suggests a deteriorating business model. Despite a recent 1-year price recovery, the long-term 5-year trend remains deeply negative (-43.5%).

ORN exhibits a fragile fundamental profile with a Piotroski F-Score of 4/9 (Stable/Weak) and a severe valuation disconnect, as the current price of $13.62 dwarfs both the Graham Number ($4.44) and the Intrinsic Value ($1.54). While revenue growth is healthy at 14.7%, the company struggles with razor-thin profit margins (0.98%) and a negative operating margin (-0.38%). Despite a 'strong_buy' analyst consensus and strong recent price momentum, the combination of a high PEG ratio (28.96), bearish insider selling, and poor earnings consistency suggests the stock is significantly overextended.